建立结合手术减瘤的卵巢癌临床相关模型以评估微转移病变治疗
研究将表达增强型荧光素酶的ID8VEGF小鼠卵巢癌细胞注射至C57Bl/6小鼠卵巢囊下,6或10周后行子宫及双侧输卵管卵巢切除术清除肉眼病灶,监测生存。结果显示手术减瘤可延长生存,早期减瘤优于延迟减瘤,模型可用于评估靶向微小残留病灶的治疗方案。
要点
- 原位注射ID8VEGF细胞可形成与人卵巢癌转移部位相似的微转移模型。
- 手术减瘤清除肉眼病灶后所有小鼠仍存在微小残留病灶。
- 早期手术减瘤比延迟减瘤生存获益更明显。
核心结论
- 原位注射建立的卵巢癌小鼠模型可模拟微转移病变,手术减瘤清除大块病灶后生存延长,早期减瘤获益优于延迟减瘤。
研究设计与样本
- 将表达增强型荧光素酶的ID8VEGF小鼠卵巢癌细胞注射至C57Bl/6小鼠卵巢囊下,在6或10周后行子宫及双侧输卵管卵巢切除术,并监测生存。
主要发现
- 增强型荧光素酶转导的ID8VEGF细胞比标准荧光素酶转导细胞更亮,可在体内可视化原位注射后发展的微小腹腔内转移。
- 手术减瘤清除了原发肿瘤但所有小鼠均残留微小病灶,转移部位与人卵巢癌转移部位相似。
- 原发与转移小鼠肿瘤的基因表达和免疫浸润相似。
- 手术减瘤较未手术延长生存,早期减瘤比延迟减瘤更有益,尽管两种情况下均存在微转移病变。
临床怎么用
- 该模型可用于评估针对已建立的微小残留病灶的靶向治疗方案。
- 提示手术减瘤清除大块病灶后,早期干预可能对微转移病变更有利。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mouse models of ovarian cancer commonly transfer large numbers of tumor cells into the peritoneal cavity to establish experimental metastatic disease, which may not adequately model early metastatic spread from a primary tumor site. We hypothesized we could develop an ovarian cancer model that predictably represents micro-metastatic disease. METHODS: Murine ID8VEGF ovarian cancer cells were transduced to express enhanced luciferase (eLuc) to enable intravital detection of microscopic disease burden and injected beneath the ovarian bursa of C57Bl/6 mice. At 6 or 10 weeks after orthotopic injection, when mice had detectable metastases, hysterectomy and bilateral salpingo-oophorectomy was performed to remove all macroscopic disease, and survival monitored. Immunohistochemistry and gene expression profiling were performed on primary and metastatic tumors. RESULTS: eLuc-transduced ID8VEGF cells were brighter than cells transduced with standard luciferase, enabling in vivo visualization of microscopic intra-abdominal metastases developing after orthotopic injection. Primary surgical cytoreduction removed the primary tumor mass but left minimal residual disease in all mice. Metastatic sites that developed following orthotopic injection were similar to metastatic human ovarian cancer sites. Gene expression and immune infiltration were similar between primary and metastatic mouse tumors. Surgical cytoreduction prolonged survival compared to no surgery, with earlier cytoreduction more beneficial than delayed, despite micro-metastatic disease in both settings. CONCLUSIONS: Mice with primary ovarian tumors established through orthotopic injection develop progressively fatal metastatic ovarian cancer, and benefit from surgical cytoreduction to remove bulky disease. This model enables the analysis of therapeutic regimens designed to target and potentially eradicate established minimal residual disease.
引用
- Morse CB, Voillet V, Bates BM, et al. Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease. Gynecol Oncol. 2020. PMID: 33229044. doi:10.1016/j.ygyno.2020.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。